Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Jessica B. Jordan"'
Autor:
Ali Alhammad, Alena Strizek, Louis S. Matza, Aishah Ekhzaimy, Jessica B Jordan, Savita B Anand, Heather L. Gelhorn, Huda Shalhoub, Kristina S. Boye
Publikováno v:
Patient Preference and Adherence. 14:2231-2242
Background The Kingdom of Saudi Arabia (KSA) has the second highest prevalence of type 2 diabetes mellitus (T2DM) in the Middle East. There is a paucity of research on the experiences and treatment preferences of patients with T2DM in KSA. This study
Autor:
Luis-Emilio Garcia-Perez, Karen G. Malley, Karin S. Coyne, Ryan T. Hietpas, Jessica B Jordan, Katie D. Stewart, Paula Wullenweber, Qianqian Wang, Maria Yu, Katelyn N. Cutts, Kristina S. Boye, Brooke M. Currie, Louis S. Matza, K. Jack Ishak
Publikováno v:
Diabetes, Obesity & Metabolism
Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference be
Autor:
Hayley Karn, Louis S. Matza, Jessica B Jordan, Silvia Del Santo, Beatrice Osumili, Gordon Parola, Katie D. Stewart, Serena Losi, Giovanni Biricolti, Magaly Perez-Nieves, Kristina S. Boye, Erik Spaepen, Ester Romoli
Publikováno v:
Diabetes Therapy
Introduction Standard concentration (100 units/mL) mealtime insulin is frequently used to treat patients with type 1 (T1D) and type 2 diabetes (T2D). A more concentrated version of the medication (200 units/mL) has been available in Italy since 2016.
Autor:
Jessica B Jordan, Louis S. Matza, Kirsi Norrbacka, Kristina S. Boye, Luis-Emilio Garcia-Perez, Ren Yu, Syed Wasi Hassan, Dara Stein
Publikováno v:
Drugs in R&D
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Introduction Patients with type 2 diabetes mellitus (T2DM) who fail to meet glycaemic control are at increased risk of diabetes complications. For patients who cannot maintain glycaemic control with oral medication, one recommended option is to add a
Publikováno v:
Diabetes Therapy
Introduction The administration of medications targeting type 2 diabetes mellitus (T2D) has evolved over time. As injection delivery systems continue to evolve, it is necessary to understand patients’ perceptions of currently available treatments.
Autor:
Heather L, Gelhorn, Kristina S, Boye, Huda, Shalhoub, Louis S, Matza, Jessica B, Jordan, Ali, Alhammad, Savita B, Anand, Aishah A, Ekhzaimy, Alena, Strizek
Publikováno v:
Patient preference and adherence
Background The Kingdom of Saudi Arabia (KSA) has the second highest prevalence of type 2 diabetes mellitus (T2DM) in the Middle East. There is a paucity of research on the experiences and treatment preferences of patients with T2DM in KSA. This study
Autor:
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas, Luis‐Emilio García‐Pérez
Publikováno v:
Diabetes, Obesity and Metabolism. 22
Autor:
Kristina S. Boye, Louis S. Matza, Rosirene Paczkowski, Jessica B Jordan, Katie D. Stewart, Lindsey Murray
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-13 (2018)
Journal of Patient-Reported Outcomes
Journal of Patient-Reported Outcomes
Background Previous research has examined patient perceptions of insulin injection devices. However, injectable medications other than insulin are increasingly used to treat type 2 diabetes, including GLP-1 receptor agonists. No patient-reported outc
Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI)
Autor:
Randall H Bender, Katie D. Stewart, Katherine Kim, Alex Mutebi, John Brazier, Alan Menter, Louis S. Matza, Hema N. Viswanathan, Lionel Pinto, Jessica B Jordan, Leon H Kircik
Publikováno v:
Journal of medical economics. 22(9)
Introduction: It is challenging to identify health state utilities associated with psoriasis because generic preference-based measures may not capture the impact of dermatological symptoms....
Autor:
Jessica B Jordan, Marco Orsini Federici, R. Gentilella, Katie D. Stewart, Kristina S. Boye, Louis S. Matza, Giovanni Biricolti, Silvia Del Santo, Kirsi Norrbacka, Serena Losi, Magaly Perez-Nieves
Aims: Several glucagon like peptide-1 (GLP-1) receptor agonists are available as weekly injections for treatment of type 2 diabetes. These medications vary in their injection devices, and these differences could impact quality-of-life and patient pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::394e504b942285139bbcef13c6995681